The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
Partnership will bring first GMP manufactured products to be sold through Valens in both Australia and New Zealand
合作伙伴關係將帶來第一批GMP製造的產品，通過Valens在兩地銷售澳大利亞和新西蘭
Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets including Latin America, Europe, UK and Asia-Pacific
進入Epsilon的GMP設施澳大利亞為Valens提供未來進入全球市場的機會，包括拉丁美洲, 歐洲、英國和亞太
KELOWNA, BC, Sept. 8, 2021 /PRNewswire/ -- The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company," "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, today announced an exclusive partnership with Epsilon Healthcare Limited (ASX:EPN) (Epsilon), a diversified global healthcare and pharmaceuticals company, for access to Epsilon's Good Manufacturing Practices (GMP) facility in Australia for manufacturing products, furthering its international expansion to GMP markets in Latin America, Europe, UK and the Asia-Pacific regions. Products will be distributed through Valens' Australian Distribution Partner, Cannvalate PTY Ltd ("Cannvalate"), and will be the largest quantity of products provided to Cannvalate for distribution to date (collectively, the "Transaction"). The partnership is reflected in the terms of the Binding Heads of Agreement between the Epsilon, THC Pharma (the Epsilon's wholly owned subsidiary, and owner of the Southport Facility), Valens, and Valens Australia Pty Ltd (Valens' wholly owned subsidiary) (the "Agreement").
公元前基洛納，9月2021年8月美通社/--瓦倫斯公司(The Valens Company Inc.)(多倫多證券交易所：VLNS)(OTCQX：VLNCF)(“公司," "這個 瓦倫斯 公司“或”瓦倫斯)，一家領先的大麻產品製造商，今天宣佈與多元化的全球保健和製藥公司Epsilon Healthcare Limited(ASX：EPN)(Epsilon)建立獨家合作伙伴關係，以獲得Epsilon位於澳大利亞的製造產品的良好製造規範(GMP)設施，進一步擴大其在澳大利亞的GMP市場拉丁美洲、歐洲、英國和亞太地區。產品將通過Valens的澳大利亞分銷合作伙伴Cannvalate Pty Ltd(“Cannvalate”)分銷，這將是迄今為止提供給Cannvalate分銷的最大數量的產品(統稱為“Cannvalate”)。交易記錄)。合作關係反映在Epsilon、THC Pharma(Epsilon的全資子公司和Southport設施的所有者)、Valens和Valens Australia Pty Ltd(Valens的全資子公司)(協議書").
With this partnership The Valens Company continues its "revenue first, capital efficient" strategy of expanding internationally. As part of the Agreement with Epsilon and Cannvalate, Valens will be provided with access to Epsilon's GMP manufacturing capabilities at the Southport Facility (as defined below) located in Queensland, Australia, the largest cannabis manufacturing facility in the Southern Hemisphere, and the largest at domestic scale with complimentary Therapeutic Good Administration (TGA) and EU GMP capabilities. The partnership also marks the first GMP manufactured products to be sold through Valens in Australia, and provides Valens with the capability to deliver GMP-grade products to Latin America, Europe, UK and Asia-Pacific.
通過這一合作伙伴關係，瓦倫斯公司繼續其“收入優先，資本效率高”的國際擴張戰略。作為與Epsilon和Cannvalate達成的協議的一部分，Valens將獲得位於澳大利亞昆士蘭的Southport工廠(定義見下文)的Epsilon的GMP製造能力。Southport工廠是南半球最大的大麻製造工廠，也是國內規模最大的工廠，具有免費的良好治療管理(TGA)和歐盟GMP能力。這一合作關係還標誌着通過Valens在澳大利亞銷售的第一個GMP製造產品，並使Valens能夠將GMP級產品交付給拉丁美洲、歐洲、英國和亞太.
Key Transaction Details:
主要交易詳情：
- The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon's GMP Manufacturing Facility in Southport, Queensland Australia (the "Southport Facility')
- Epsilon's Southport Facility is the largest cannabis extraction facility in the Southern Hemisphere with TGA and EU GMP capability
- Valens to fund all operational and capital expenditure of the Southport Facility in return for preferential access for up to 85 percent of the operational capacity of the Southport Facility over the next five years, with an option to extend this arrangement for an additional six years
- Valens to provide operational and management consultancy at the Southport Facility to bring their industry-leading intellectual property, technology, and team to the Southport Facility to take advantage of Epsilon's GMP Manufacturing capability
- Marks first foray into EU GMP medicine production for Valens
- The Agreement compliments its existing partnership with Cannvalate opening up GMP manufactured products to be sold through Cannvalate's distribution network First products manufactured under strategic alliance expected to be delivered in the coming weeks
- 加拿大領先的大麻產品製造商Valens公司已經與Epsilon公司建立了長期合作伙伴關係，獨家進入Epsilon的GMP製造設施。南波特, 澳大利亞昆士蘭(“南港設施')
- Epsilon的南港設施是南半球最大的大麻提取設施，具有TGA和歐盟GMP能力
- Valens將為南港融資機制的所有運營和資本支出提供資金，以換取在未來五年內優先獲得南港融資機制高達85%的運營能力，並有權將這一安排再延長六年
- Valens將在Southport工廠提供運營和管理諮詢，將其業界領先的知識產權、技術和團隊帶到Southport工廠，以利用Epsilon的GMP製造能力
- 標誌着Valens首次進軍歐盟GMP藥品生產
- 該協議是對其與Cannvalate現有合作伙伴關係的補充，打開了GMP製造的產品將通過Cannvalate的分銷網絡銷售，第一批根據戰略聯盟製造的產品預計將在未來幾周內交付
Epsilon's wholly owned subsidiary, THC Pharma Pty Ltd (THC Pharma) operates a TGA and Office of Drug Control (ODC) licensed medicinal cannabis manufacturing facility with TGA and EU GMP capabilities in Southport, Queensland Australia. THC Pharma's GMP Southport facility is a 10,000 square foot purpose-built botanicals extraction facility capable of extraction of raw plant material and downstream purification and isolation processing. The facility consists of its own QC lab and grade D cleanroom space for the manufacture of oral dose format products. Epsilon also owns a number of medicinal cannabis assets, including the Tetra Health clinic, and the Medimar Platform – an end-to-end ecommerce solution for nutraceuticals and cannabis. Epsilon also operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.
Epsilon的全資子公司THC Pharma Pty Ltd(THC Pharma)在南港經營着一家TGA和藥物管制辦公室(ODC)許可的醫用大麻生產設施，具有TGA和歐盟GMP能力。澳大利亞昆士蘭。THC Pharma的GMP Southport工廠是一個10,000平方英尺的專門建造的植物提取設施，能夠提取植物原料以及下游的提純和分離處理。該設施由自己的QC實驗室和D級潔淨室組成，用於生產口服劑量格式的產品。Epsilon還擁有一些醫用大麻資產，包括利樂健康診所和Medimar平臺--這是一個針對營養食品和大麻的端到端電子商務解決方案。Epsilon還經營着一家總部設在加拿大温哥華的交鑰匙大麻種植解決方案提供商。
"With this partnership we have fulfilled our promise to achieve GMP manufacturing in 2021 and we have gained access to international cannabis markets through the 'Valens way,' utilizing an asset-light approach that allows us to export to GMP markets globally. We are excited to work with the largest and most advanced cannabis manufacturing facility in the Southern Hemisphere to distribute GMP products, and look forward to advancing our product distribution capabilities through our continued partnership with Cannvalate. We believe this strategic partnership is an efficient use of capital towards accessing GMP quality products and accelerates our timeline to market dramatically," said Tyler Robson, Chief Executive Officer and Chair of The Valens Company. "With the rapid unit volume growth coming out of our K2 facility that was built to GMP standards, we believe this agreement offers us the best of both worlds - access to GMP manufacturing without giving up on domestic revenue growth opportunities."
通過這一合作伙伴關係，我們實現了在2021年實現GMP生產的承諾，我們已經通過‘Valens Way’獲得了進入國際大麻市場的機會，利用資產輕量化的方法，使我們能夠向全球GMP市場出口。我們很高興與南半球最大、最先進的大麻製造設施合作分銷GMP產品，並期待通過與Cannvalate的持續合作來提高我們的產品分銷能力。我們相信，這種戰略夥伴關係是對資本的有效利用，有助於獲得GMP質量產品，並加快我們的隨着我們按照GMP標準建造的K2工廠產量的快速增長，我們相信這項協議為我們提供了兩全其美的機會--在不放棄國內收入增長機會的情況下獲得GMP製造。“
Jarrod White, Chief Executive Officer of Epsilon noted, "This year alone, Valens has grown exponentially not only across provinces and territories in Canada, but in the US as well, which is an excellent platform for the growth we see forthcoming in the international Medicinal Cannabis market generally. Epsilon's partnership with Valens as a leading manufacturer of cannabis products is complementary to our facility, being the largest TGA and EU GMP facility in the Southern Hemisphere. We are excited to be working with Valens during such a flourishing time in their corporate trajectory. Valens also shows a promising production throughput to scale up our GMP manufacturing capability. We look forward to furthering our partnership with Valens in the coming months as we accelerate the commercial production output from Epsilon's wholly owned facility."
Epsilon公司首席執行官賈羅德·懷特(Jarrod White)指出：“僅今年一年，Valens不僅在中國各省和地區呈指數級增長。加拿大，但在美國也是如此，這是我們看到國際藥用大麻市場總體上即將出現的增長的一個極好的平臺。作為一家領先的大麻產品製造商，Epsilon與Valens的合作伙伴關係是對我們設施的補充，我們的設施是南半球最大的TGA和歐盟GMP設施。我們很高興能與瓦倫斯合作，在他們的公司發展軌跡如此繁榮的時期與他們合作。瓦倫斯還展示了很有希望的生產能力，以擴大我們的GMP製造能力。我們期待着在未來幾個月裏進一步加強我們與Valens的夥伴關係，因為我們正在加速Epsilon全資擁有的設施的商業生產產出。“
Dr. Sud Agarwal, Chief Executive Officer of Cannvalate added, "Having worked closely with Valens for over a year, we have already noticed significant growth in their market share in the APAC market. Now, with access to a GMP facility via our partnership with Epsilon, we forecast a dramatic increase in demand both domestically and internationally. With New Zealand moving to a pureplay GMP market in October 2021 and the Australian Government indicating they will too in the very near future, we see this opportunity as building a significant competitive advantage for the Valens-Cannvalate partnership."
Cannvalate首席執行官Sud Agarwal博士補充説：“在與Valens密切合作一年多之後，我們已經注意到他們在亞太地區市場的市場份額有了顯著增長。現在，通過我們與Epsilon的合作伙伴關係獲得GMP設施，我們預測國內和國際需求將大幅增加。新西蘭2021年10月進入一個純粹的GMP市場，澳大利亞政府表示他們也將在不久的將來進入GMP市場，我們認為這一機會將為Valens-Cannvalate夥伴關係建立重要的競爭優勢。“
This initial production run is the first milestone of Valens' partnership with Epsilon. Valens anticipates that the partnership will see further expansion as it receives additional orders for GMP product globally.
首次投產是Valens與Epsilon合作的第一個里程碑。Valens預計，隨着它在全球收到更多GMP產品的訂單，這一合作伙伴關係將進一步擴大。
Further details concerning the Transaction as set forth in Schedule 1 below.
以下附表1所列有關交易的進一步詳情。
At Valens, it's Personal.
在瓦倫斯，這是私人恩怨。
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company's high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada's only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company and its subsidiaries at http://www.thevalenscompany.com.
關於瓦倫斯公司
瓦倫斯公司是一家領先的大麻產品製造商，其使命是將大麻的好處帶給世界。該公司除了提供同類最好的產品開發、製造和大麻消費包裝商品的商業化外，還提供專有的大麻加工服務。Valens公司的高質量產品是為醫療、健康和娛樂消費細分市場制定的，在所有大麻產品類別中都有提供，注重質量和創新。該公司還通過其子公司Green Roads在美國製造、分銷和銷售各種CBD產品，並將藥用大麻產品分銷給澳大利亞通過其子公司Valens Australia。通過與全球各地的品牌公司、消費品公司和特許大麻生產商合作，該公司繼續擴大其多樣化的產品組合，以適應關鍵市場不斷變化的大麻消費者偏好。通過Valens Labs，該公司正在制定大麻測試和研發的標準，加拿大的僅有ISO17025認證的分析服務實驗室，被合作伙伴和科學世界領先者Thermo Fisher Science命名為植物科學卓越中心。欲瞭解有關瓦倫斯公司及其子公司的更多信息，請訪問http://www.thevalenscompany.com.。
About Epsilon Healthcare Limited
Epsilon Healthcare (ASX:EPN) is an ASX listed diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic, and the Medimar Platform. EPN's manufacturing facility is a fully licensed and permitted Australian TGA and EU GMP bio-floral extraction facility with a range of approved GMP licensed products and formulations. EPN's facility is capable of product development, manufacturing, and commercialization of cannabis consumer packaged goods in addition to the manufacture of products and formulations for use in clinical trials to a TGA and EU GMP standard. EPN additionally operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.
關於Epsilon Healthcare Limited
Epsilon Healthcare(澳大利亞證券交易所股票代碼：EPN)是一家在澳大利亞證券交易所上市的多元化全球醫療保健和製藥公司。EPN擁有許多醫用大麻資產，包括南半球最大的GMP大麻製造設施、利樂健康診所和Medimar平臺。EPN的製造設施是一家獲得完全許可的澳大利亞TGA和歐盟GMP生物花卉提取設施，擁有一系列經批准的GMP許可產品和配方。除了按照TGA和歐盟GMP標準生產用於臨牀試驗的產品和配方外，EPN的設施還能夠進行大麻消費包裝產品的產品開發、製造和商業化。EPN還經營着一家總部設在加拿大温哥華的交鑰匙大麻種植解決方案提供商。
About Cannvalate
Cannvalate is Australia's largest business-to-business services company supporting both domestic and international Medicinal Cannabis companies fast track their growth into the Australian market. Their two key services include:
關於Cannvalate
Cannvalate是澳大利亞最大的企業對企業服務公司，為國內和國際藥用大麻公司快速進入澳大利亞市場提供支持。他們的兩項關鍵服務包括：
- ACMA (Australian Cannabis Market Access) – Australia's largest network of medicinal cannabis prescribing clinics, consisting of more than 2,400 referring physicians and 600 affiliated pharmacies spanning all states of Australia. Cannvalate prescriptions currently account for almost 50% of the Australian market, which is now the fastest growing pure-play medical market in the world.
- Medicinal Cannabis Research Collaboration (MCRC) – The world's only cannabis-specialised, Clinical Research Organisation (CRO) providing best-in-class, cost-effective, clinical and preclinical research. The MCRC provides end-to-end, novel cannabinoid drug discovery in conjunction with a talented, commercially-orientated, scientific team, capable of performing preclinical, phase 1, phase 2 and phase 3 trials.
- ACMA(澳大利亞大麻市場準入)-澳大利亞的最大的藥用大麻處方診所網絡，由2400多名轉診醫生和600多家附屬藥房組成，遍及所有州澳大利亞。Cannvalate處方藥目前佔據了澳大利亞市場近50%的份額，澳大利亞現在是世界上增長最快的純藥物市場。
- 大麻藥用研究合作組織(MCRC)--世界上唯一專門從事大麻研究的臨牀研究組織(CRO)，提供同類最佳、成本效益高的臨牀和臨牀前研究。MCRC與一支才華橫溢、以商業為導向的科學團隊合作，提供端到端的新型大麻類藥物發現，能夠進行臨牀前、第一階段、第二階段和第三階段的試驗。
Schedule 1
附表1
The material terms of the Binding Heads of Agreement between the Epsilon, THC Pharma (the Epsilon's wholly owned subsidiary, and owner of the Southport Facility), Valens, and Valens Australia Pty Ltd (Valens' wholly owned subsidiary) (Valens AU) are provided below:
Epsilon、THC Pharma(Epsilon的全資子公司和Southport設施的所有者)、Valens和Valens Australia Pty Ltd(Valens的全資子公司)(Valens AU)之間具有約束力的協議頭的實質性條款如下：
| 1. | The Parties must use their best endeavours to execute the following documentation by 30 November 2021 to formalize the terms in the Binding Heads of Agreement: | |
| | a. | The Epsilon-Valens Management/Operational Consultancy |
| | | (the "Operational Agreement"); and |
| | b. | The Epsilon-Valens Export Supply Agreement (the "Export Supply Agreement") |
| | | (together, the "Definitive Agreements"). |
| 2. | The conditions precedent for the execution of the Definitive Agreements are: | |
| | a. | Epsilon and THC Pharma being satisfied that their entry to the Definitive Agreements will not jeopardize any regulatory license or other authorization held by THC Pharma (including any license or authorization granted by the Therapeutic Goods Administration or the Office of Drug Control); |
| | b. | Each of the Parties obtaining all required authorizations from any Government agency or regulatory body including, but not limited to, the Therapeutic Goods Administration and the Office of Drug Control. |
| 3. | The material terms of the Operational Agreement are: | |
| | a. | Valens and/or Valens AU will provide management and operational consultancy services to THC Pharma in respect of its manufacture of medicinal cannabis and medicinal cannabis products for supply to the Australian and international markets, including a license to use Valens know-how and other intellectual property rights regarding the manufacture of medicinal cannabis products. |
| | b. | During the term of the Operational Agreement, Valens will cover the cost of all THC Pharma's operational and capital expenditure. In return for priority access to THC Pharma's manufacturing output. |
| | c. | Valens will leverage its preferred partnership with Cannvalate to sell GMP products manufactured in the Epsilon Southport Facility for sale in Australia or New Zealand. |
| | d. | THC Pharma will pay Valens a management fee on all medicinal cannabis products manufactured by THC Pharma for Valens customers such that in effect THC Pharma retains a 'royalty' of 2.5% to 4% of sales revenue for all Valens customer products. |
| | e. | THC Pharma will pay Valens a management fee on all medicinal products manufactured by THC Pharma for its own customers being the cost of production plus 25%, or such other amount the parties agree after good faith negotiations. |
| | f. | Valens is required to use the Epsilon Southport Facility for all production of medicinal cannabis products for sale in Australian or New Zealand. |
| | g. | The term of the agreement is for a minimum of five years, with an additional five year option, and a final 12 month option, each of which can be exercised at Valens's discretion. |
| 4. | The Operational Agreement may otherwise only be terminated in the event of a material increase in the monthly forecasted costs or annual costs of the facility over a continuous period, in the event of a failure to meet regulatory and statutory requirements, a breach of law or regulation, a change of control of THC Pharma, or failure to meet specified confidential performance criteria under the Agreement for two consecutive quarters.The material terms of the Export Supply Agreement are: | |
| | a. | Valens AU appoints THC Pharma as its contract manufacturer for the manufacture of medicinal cannabis products in Australia at the order of Valens AU for export from Australia by Valens AU to Valens customers. |
| | b. | Valens AU will be the 'sponsor' of the product for Australian compliance purposes and will be responsible for all regulatory obligations as the sponsor of the products. |
| | c. | The term of the agreement is for a minimum of five years, with an additional five year option, and a final 12 month option, each of which can be exercised at Valens's discretion. |
| 1. | 雙方必須盡最大努力在2021年11月30日之前簽署以下文件，以正式確定具有約束力的協議頭部中的條款： | |
| | a. | Epsilon-Valens管理/運營諮詢公司 |
| | | (“營運協議”)；及 |
| | b. | Epsilon-Valens出口供應協定(“出口供應協定”) |
| | | (統稱為“最終協議”)。 |
| 2. | 簽署最終協議的先決條件是： | |
| | a. | Epsilon和THC Pharma確信它們加入最終協議不會危及THC Pharma持有的任何監管許可或其他授權(包括治療藥品管理局或藥物管制辦公室授予的任何許可或授權)； |
| | b. | 每一方均獲得任何政府機構或監管機構(包括但不限於治療用品管理局和藥物管制辦公室)的所有必要授權。 |
| 3. | 《運營協議》的具體條款如下： | |
| | a. | Valens和/或Valens AU將為THC Pharma公司生產藥用大麻和藥用大麻產品提供管理和運營諮詢服務，以供應澳大利亞和國際市場，包括獲得使用Valens技術和其他知識產權製造藥用大麻產品的許可證。 |
| | b. | 在運營協議期限內，Valens將支付THC Pharma的所有運營和資本支出。作為交換，他們優先獲得THC Pharma的製造產量。 |
| | c. | 瓦倫斯公司將利用其與坎瓦萊特公司的優先合作伙伴關係，銷售在Epsilon Southport工廠生產的GMP產品，並在澳大利亞或新西蘭銷售。 |
| | d. | THC製藥公司將向Valens公司支付THC製藥公司為Valens客户生產的所有醫用大麻產品的管理費，這樣THC Pharma公司實際上將保留所有Valens客户產品銷售收入的2.5%至4%的“特許權使用費”。 |
| | e. | THC Pharma將向Valens支付THC Pharma為其客户生產的所有醫藥產品的管理費，即生產成本加25%，或經雙方真誠談判後達成的其他金額。 |
| | f. | Valens被要求使用Epsilon Southport設施生產所有在澳大利亞或新西蘭銷售的醫用大麻產品。 |
| | g. | 協議期限至少為五年，另外還有五年選擇權和最後12個月選擇權，每一項都可以由瓦倫斯酌情行使。 |
| 4. | 否則，只有在設施的月度預測成本或年度成本連續兩個季度大幅增加、未能滿足監管和法定要求、違反法律或法規、THC醫藥控制權變更或未能滿足協議規定的保密性能標準的情況下，運營協議才可終止。出口供應協議的主要條款為： | |
| | a. | 根據Valens AU的訂單，Valens AU指定THC Pharma為其在澳大利亞生產醫用大麻產品的合同製造商，由Valens AU向Valens客户出口。 |
| | b. | 出於澳大利亞合規的目的，Valens AU將成為該產品的“贊助商”，並將作為該產品的贊助商承擔所有監管義務。 |
| | c. | 協議期限至少為五年，另外還有五年選擇權和最後12個月選擇權，每一項都可以由瓦倫斯酌情行使。 |
There can however be no assurance that the Definitive Agreement will be entered into.
然而，不能保證最終協議會達成。
Notice regarding Forward Looking Statements
關於前瞻性陳述的通知
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "plans", "expects", "scheduled", "trends", "forecasts", "future", "indications", "potential", "estimates", "predicts", "anticipate", "to establish", "believe", "intend", "ability to", or statements that certain actions, events or results "may", "should", "could", "would", "might", "will", or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
本新聞稿中包含的所有信息，包括有關未來財務或經營業績的任何信息，以及表達管理層對未來業績的預期或估計的其他陳述(歷史事實陳述除外)，均構成適用證券法意義上的前瞻性信息或前瞻性陳述，基於截至本新聞稿發佈之日的預期、估計和預測。包括前瞻性陳述的目的是提供有關管理層目前對未來的期望和計劃的信息。凡有可能，如“計劃”、“預期”、“預定”、“趨勢”、“預測”、“未來”、“跡象”、“潛在”、“估計”、“預測”、“預期”、“建立”、“相信”、“打算”、“能力”或某些行動、事件或結果“可能”、“應該”、“可能”、“將會”、“可能”、“將會”或“可能”採取的聲明，這些詞語的否定或其其他變體已被用於識別此類前瞻性信息。具體的前瞻性陳述包括但不限於關於未來經營結果、交易未來結果、經濟狀況和預期行動方案的所有披露。建議投資者和其他各方注意，製造和發運SKU的數量與收入和利潤之間不一定存在任何關聯，不應過度依賴此類信息。
The risks and uncertainties that may affect forward-looking statements include, among others, , Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
可能影響前瞻性表述的風險和不確定性包括但不限於加拿大監管風險、澳大利亞監管風險、美國監管風險、美國過境和旅行禁令、“新冠肺炎”大流行病的不確定性、影響和應對措施、對許可證的依賴、設施的擴建、競爭、對大麻供應和其他關鍵投入的依賴、對高級管理人員和關鍵人員的依賴、一般業務風險和責任、大麻行業監管、法律、法規和指導方針的變化以及遵守法律的情況。有限的經營歷史、易受能源成本上升的影響、不利的宣傳或消費者認知、產品責任、與知識產權相關的風險、產品召回、預測困難、增長管理和訴訟，其中許多都超出了Valens公司的控制範圍。有關Valens公司面臨的風險的更全面討論，這些風險可能導致Valens公司的實際財務結果、業績或成就與前瞻性信息或前瞻性陳述中明示或暗示的估計未來結果、業績或成就大不相同，請參閲Valens公司提交給加拿大證券監管機構的最新年度信息表(www.sedar.com)或Valens公司網站www.thevalenscompany.com。該年度信息表中描述的風險在此通過引用併入本文。儘管本文中包含的前瞻性陳述反映了管理層當前的信念和基於截至本文發佈之日管理層可獲得的信息的合理假設, Valens公司不能確定實際結果是否與這些前瞻性信息一致。Valens公司告誡您不要過度依賴任何此類前瞻性陳述。除非適用法律要求，否則Valens公司不會因為新信息、未來事件或其他原因而更新或修改任何前瞻性陳述，也不承擔任何義務。本協議中的任何內容均不得解釋為出售Valens公司證券的要約或購買或出售Valens公司證券的邀約。
CONTACT : Jeff Fallows, President, The Valens Company, Investor Relations, ir@thevalenscompany.com, 1 647.956.8254; KCSA Strategic Communications, Phil Carlson / Elizabeth Barker, VLNS@kcsa.com, 1 212.896.1233 / 1 212.896.1203; Media, KCSA Strategic Communications, Anne Donohoe, adonohoe@kcsa.com, 1 212.896.1265
電子郵件：ir@thevalenscompany.com，1 647.956.8254；KCSA Strategic Communications，菲爾·卡爾森/Elizabeth Barker，VLNS@kcsa.com，1 212.896.1233/1 212.896.1203；媒體，KCSA Strategic Communications，安妮·多諾霍電子郵件：adonohoe@kcsa.com，1 212.896.1265
Related Links :
相關鏈接：
https://thevalenscompany.com/
Https://thevalenscompany.com/
譯文內容由第三人軟體翻譯。